Atara Biotherapeutics Inc. (NASDAQ:ATRA) fell 1.5% during trading on Tuesday after an insider sold shares in the company. The company traded as low as $15.75 and last traded at $15.90, with a volume of 63,613 shares. The stock had previously closed at $16.15.
Specifically, insider Christopher Haqq sold 1,346 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $22.32, for a total value of $30,042.72. Following the transaction, the insider now directly owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,800 shares of the company’s stock in a transaction that occurred on Friday, October 14th. The shares were sold at an average price of $15.96, for a total value of $76,608.00. Following the completion of the transaction, the chief executive officer now directly owns 549,136 shares in the company, valued at $8,764,210.56. The disclosure for this sale can be found here. 16.10% of the stock is owned by insiders.
Several equities analysts recently issued reports on ATRA shares. Jefferies Group reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Atara Biotherapeutics in a research report on Sunday, July 10th. JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 10th. Citigroup Inc. upped their price objective on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research report on Friday, August 19th. Finally, Goldman Sachs Group Inc. cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $26.14.
The stock’s market cap is $455.21 million. The firm’s 50-day moving average is $19.53 and its 200-day moving average is $20.24.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. Equities analysts predict that Atara Biotherapeutics Inc. will post ($2.85) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in ATRA. Barclays PLC boosted its stake in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares in the last quarter. BlackRock Inc. boosted its stake in Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares in the last quarter. Creative Planning bought a new stake in Atara Biotherapeutics during the third quarter worth approximately $213,000. Finally, Franklin Street Advisors Inc. NC bought a new stake in Atara Biotherapeutics during the third quarter worth approximately $214,000. 75.58% of the stock is owned by institutional investors and hedge funds.